{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:17:35Z","timestamp":1756635455879},"reference-count":29,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/terarkh201587972-76","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T17:45:34Z","timestamp":1460655934000},"page":"72","source":"Crossref","is-referenced-by-count":3,"title":["Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases"],"prefix":"10.26442","volume":"87","author":[{"given":"S. A.","family":"Smakotina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Zelendinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. N.","family":"Bondareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh201587972-76-1","unstructured":"Popkova T.V., Novikova D.S., Nasonov E.L. Ateroskleroz pri revmaticheskikh zabolevaniyakh. V kn.: Revmatologiya: klinicheskie rekomendatsii. M.: GEOTAR-Media; 2010:678-702."},{"key":"key-10.17116\/terarkh201587972-76-2","doi-asserted-by":"crossref","unstructured":"Peters MJ, Symmons DP, McCarey DW et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis \u2014 TASK FORCE \u00abCardiovascular risk management in RA\u00bb. Ann Rheum Dis. 2010;69(2):325-331.","DOI":"10.1136\/ard.2009.113696"},{"key":"key-10.17116\/terarkh201587972-76-3","doi-asserted-by":"crossref","unstructured":"Van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis. 2009;68:1395-1400.","DOI":"10.1136\/ard.2008.094151"},{"key":"key-10.17116\/terarkh201587972-76-4","doi-asserted-by":"crossref","unstructured":"Maradit-Kremers H, Crowson CS, Therneau TM et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arthr Rheum. 2008;58(8):2268-2274.","DOI":"10.1002\/art.23650"},{"key":"key-10.17116\/terarkh201587972-76-5","doi-asserted-by":"crossref","unstructured":"Goodson NI, Willes NJ, Lunt NC. Mortality on early inflamatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum. 2002;46:2010-2019.","DOI":"10.1002\/art.10419"},{"key":"key-10.17116\/terarkh201587972-76-6","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthr Rheum. 2005;35:8-17.","DOI":"10.1016\/j.semarthrit.2005.03.004"},{"key":"key-10.17116\/terarkh201587972-76-7","doi-asserted-by":"crossref","unstructured":"Gerli R, Bartoloni Bocci E, Sherer Y et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724-725.","DOI":"10.1136\/ard.2007.073718"},{"key":"key-10.17116\/terarkh201587972-76-8","doi-asserted-by":"crossref","unstructured":"Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum. 2009;61:419-424.","DOI":"10.1002\/art.24390"},{"key":"key-10.17116\/terarkh201587972-76-9","doi-asserted-by":"crossref","unstructured":"Meune C, Touze E, Trinqurte L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology. 2009;48(10):1309-1313.","DOI":"10.1093\/rheumatology\/kep252"},{"key":"key-10.17116\/terarkh201587972-76-10","unstructured":"Gazi IF, Boumpas DT, Mikhailidis DP et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheum. 2007;25:102-111."},{"key":"key-10.17116\/terarkh201587972-76-11","unstructured":"Popkova T.V., Novikova D.S., Novikov A.A. i dr. Rol' narushenii v sisteme transporta kholesterina krovi v razvitii ateroskleroza pri revmatoidnom artrite. Nauchno-prakticheskaya revmatologiya. 2007;5:4-10."},{"key":"key-10.17116\/terarkh201587972-76-12","unstructured":"Popkova T.V., Novikova D.S., Gerasimova E.V. i dr. Znachenie faktorov riska v prognozirovanii klinicheskikh proyavlenii ateroskleroza pri SKV i RA. Sb. mater. V s''ezda revmatologov Rossii. M.; 2009:91."},{"key":"key-10.17116\/terarkh201587972-76-13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.277"},{"key":"key-10.17116\/terarkh201587972-76-14","doi-asserted-by":"crossref","unstructured":"Nurmohamed M, Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68:453-455.","DOI":"10.1136\/ard.2008.104497"},{"key":"key-10.17116\/terarkh201587972-76-15","unstructured":"Nielen MJ, van Halm VP, Nurmohamed MT et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum. 2003;48:344."},{"key":"key-10.17116\/terarkh201587972-76-16","doi-asserted-by":"crossref","unstructured":"Van Halm VP, Nielen MJ, Nurmohamed MT et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2006;3:1-5.","DOI":"10.1136\/ard.2006.051672"},{"key":"key-10.17116\/terarkh201587972-76-17","doi-asserted-by":"crossref","unstructured":"Myasoedova E, Gabriel S. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol. 2010;22:342-347.","DOI":"10.1097\/BOR.0b013e3283379b91"},{"key":"key-10.17116\/terarkh201587972-76-18","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.277"},{"key":"key-10.17116\/terarkh201587972-76-19","unstructured":"Curtis J, John A, Baser O et al. Frequency of lipid testing in patients with rheumatoid arthritis: a retrospective database analysis. Arthr Rheum. 2009;60(Suppl. 10):s516."},{"key":"key-10.17116\/terarkh201587972-76-20","doi-asserted-by":"crossref","unstructured":"Toms TE, Panoulas VF, Douglas KM et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann Rheum Dis. 2009;Oct 23 [Epub. ahead of print].","DOI":"10.1136\/ard.2009.115717"},{"key":"key-10.17116\/terarkh201587972-76-21","unstructured":"Okamoto H, Koizumi K, Kamitsuji S et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34:964-968. http:\/\/www.cardiosite.ru."},{"key":"key-10.17116\/terarkh201587972-76-22","unstructured":"Shevchenko O.P., Shevchenko A.O. Statiny. Ingibitory GMG-KoA reduktazy. M.: Reafarm; 2002."},{"key":"key-10.17116\/terarkh201587972-76-23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.1433"},{"key":"key-10.17116\/terarkh201587972-76-24","unstructured":"Charles-Schoeman C, Khanna D, Furst DE et al. Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study. J Rheumatol. 2007;34(7):1458-1464."},{"key":"key-10.17116\/terarkh201587972-76-25","unstructured":"Dyadyk A.I., Bagrii A.E., Stulikova E.L. i dr. Primenenie atorvastatina u bol'nykh revmatoidnym artritom. Ukrainskii revmatologicheskii zhurnal. 2006;3(25):38-41."},{"key":"key-10.17116\/terarkh201587972-76-26","doi-asserted-by":"crossref","unstructured":"Lien LM, Hsieh YC. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan. Atherosclerosis. 2010;212(2):595-600.","DOI":"10.1016\/j.atherosclerosis.2010.05.040"},{"key":"key-10.17116\/terarkh201587972-76-27","doi-asserted-by":"crossref","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.","DOI":"10.1001\/jama.291.9.1071"},{"key":"key-10.17116\/terarkh201587972-76-28","doi-asserted-by":"crossref","unstructured":"Cannon CP, Braunwald E, Mc. Cabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:15-24.","DOI":"10.1056\/NEJMoa040583"},{"key":"key-10.17116\/terarkh201587972-76-29","doi-asserted-by":"crossref","unstructured":"Khush KK, Waters D. Higher dose of potent statin better for high-risk patients. Cleveland Clin J Med. 2004;1:609-616.","DOI":"10.3949\/ccjm.71.8.609"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:24:54Z","timestamp":1593379494000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2015\/9\/downloads\/ru\/460040-366020150911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"alternative-id":["terarkh201587972-76"],"URL":"https:\/\/doi.org\/10.17116\/terarkh201587972-76","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}